drugset / Trial / NCT00338130

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

NCT00338130

Phase 2 Completed 239 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to compare the efficacy of AZD6244 (ARRY-142886) with temozolomide in patients with advanced melanoma

Timeline

Start
2006-07
Primary completion
2007-09
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule Oral
Comparator Temozolomide Small molecule Oral

Indications